ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

被引：1

作者：

Lonial, Sagar

Dimopoulos, Meletios A.

Palumbo, Antonio

White, Darrell

Grosicki, Sebastian

Spicka, Ivan

Walter-Croneck, Adam

Moreau, Philippe

Mateos, Maria-Victoria

Magen-Nativ, Hila

Belch, Andrew

Reece, Donna Ellen

Beksac, Meral

Taniwaki, Masafumi

Roellig, Christoph

Singhal, Anil K.

Katz, Jessica

Bleickardt, Eric W.

Poulart, Valerie

Richardson, Paul G.

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[2] Univ Athens, Athens 11528, Greece

[3] AOU San Giovanni Battista Torino, Osped Molinette, Turin, Italy

[4] Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada

[5] Silesian Med Univ, Fac Publ Hlth, Dept Canc Prevent, Katowice, Poland

[6] Prague Gen Hosp, Prague, Czech Republic

[7] Med Univ Lublin, Lublin, Poland

[8] Univ Hosp, Nantes, France

[9] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[10] Tel Aviv Univ, Ramat Aviv, Israel

[11] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[12] Univ Alberta, Edmonton, AB, Canada

[13] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[14] Ankara Univ, TR-06100 Ankara, Turkey

[15] Kyoto Prefectural Univ Med, Kyoto, Japan

[16] Univ Klinikum TU, Dresden, Germany

[17] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA

[18] Bristol Myers Squibb Co, Princeton, NJ USA

[19] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[20] Bristol Myers Squibb, Braine Lalleud, Belgium

[21] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8508

引用

页数：1